Linezolid solution

Linezolid solution purchased from MedChemExpress. Usage Cited in: Nat Microbiol. 2025 Nov;10(11):2875-2891. [Abstract]

Customer Validation
Dose-response curves for Linezolid (LZD: 0.0625-256 μg/mL) against M. abscessus ∆eis2 or M. abscessus Eis2 T258R strains complemented with pOLYG-aac(3)IV-eis2 overexpression or pOLYG-aac(3)IV control vector.

Linezolid solution purchased from MedChemExpress. Usage Cited in: Nat Microbiol. 2025 Nov;10(11):2875-2891. [Abstract]

Customer Validation
Efficacy of CLR, Linezolid (LZD: 100 mg/kg) and FF-NH2 versus saline vehicle in an acute mouse infection model. GM-CSF KO mice were infected with M. abscessus WT, treatment began on day 2 and continued for 9 days (CLR/LZD oral daily, FF-NH2 subcutaneous twice daily). Bacterial burden (colony forming units (c.f.u.)) was measured in lung, liver and spleen at day 12 post-infection.

Linezolid solution purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2023 Jul 1;242(Pt 1):124750. [Abstract]

Customer Validation
MH-S cells were pretreated with insulin, linezolid, or combination of insulin (50 nmol/L) and Linezolid (0.25 μg/ml) for 1 h, next these cells were treated with high glucose (30 mmol/L) and/or S. aureus 8325–4, high glucose and/or S. aureus DU1090 for 4 h, then the cell viability was tested by CCK8 kit;

Linezolid solution purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2023 Jul 1;242(Pt 1):124750. [Abstract]

Customer Validation
MH-S cells were pretreated with insulin, linezolid, or a combination of insulin (50 nmol/L) and linezolid (0.25 μg/ml) for 1 hour, and then treated with high glucose (30 mmol/L) and/or Staphylococcus aureus 8325-4, or high glucose and/or Staphylococcus aureus DU1090 for 4 hours. The glucose content in the MH-S cell culture medium was detected using a glucose content detection kit.

Linezolid solution purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2023 Jul 1;242(Pt 1):124750. [Abstract]

Customer Validation
MH-S cells were pretreated with insulin, linezolid and combination of insulin (50 nmol/L) and Linezolid (0.25 μg/ml) for 1 h, next these cells were treated with high glucose (30 mmol/L) and/or S. aureus 8325–4 (1 × 107 CFUs), high glucose and/or S. aureus DU1090 (1 × 107 CFUs) for 4 h. Then the expressions of TLR2, MAPKs (JNK, ERK, p38, p-JNK, p-ERK1/2, and p-p38), NLRP3 inflammasome proteins (NLRP3, ASC, Caspase-1, IL-1β, IL-18) and MIP-2 were detected by each pathway inhibitor treatment was used to further explore the upstream and downstream relationships among TLR2, MAPKs and NLRP3-related inflammatory pathways in MH-S cells.